New 3-in-1 Blood Pressure Medication Approved by the FDA

Credit: Adobe Stock/interstid

A new option to treat high blood pressure is coming soon — and it could make a big difference for the millions of people who need more than one medication to manage their condition. On June 9, 2025, the U.S. Food and Drug Administration (FDA) approved Widaplik (also known as GMRx2) to treat high blood pressure in adults.

Widaplik is expected to launch in the U.S. in late 2025.

Why This Matters

Nearly one in two adults in the U.S. has high blood pressure — but only about one in four has it under control. Often, people need more than one medication to reach healthy blood pressure levels, and managing multiple pills can be a challenge.

Widaplik may help simplify that process. It’s a once-daily pill that combines three proven medications into one:

• Telmisartan: helps relax blood vessels
• Amlodipine: a calcium channel blocker that helps blood flow more easily
• Indapamide: a mild diuretic that helps reduce excess fluid in the body

By combining these medications into a single tablet, Widaplik offers a convenient, effective option for people who may otherwise need to juggle several prescriptions.

Who Is It For?

Widaplik is the first and only triple-combination medication approved in the U.S. for initial treatment in patients who are likely to need more than one medication to reach their blood pressure goals. It comes in three dose strengths, including two lower-dose options, which allows doctors to tailor the treatment to individual needs.

According to Paul Whelton, M.D., M.Sc., a leading hypertension expert from Tulane University, “Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatments.”

What the Research Shows

The approval of Widaplik is based on international phase 3 clinical trials, which showed that the drug significantly did the following:

• Lowered blood pressure
• Improved blood pressure control rates
• Was well tolerated, with low rates of side effects

Another major study, called the VERONICA trial, compared Widaplik with standard treatments and found that it worked better at lowering blood pressure — again with good tolerability.

The most common side effect seen was symptomatic hypotension, which is a drop in blood pressure that can cause dizziness or fainting. For safety reasons, Widaplik should not be used by the following:

• People who cannot produce urine (a condition called anuria)
• People who are allergic to any of the medications in the pill

What’s Next

Widaplik’s manufacturer, George Medicines, is planning to launch the medication in the U.S. by the end of 2025 and submit it for approval in other countries soon after. The drug is also being studied in a large global trial to see whether it can help prevent stroke in people who’ve had a type of bleeding stroke known as intracerebral hemorrhage.

“With its triple combination efficacy, established safety profile, good tolerability and its availability in a single pill, Widaplik has the potential to address key challenges in current hypertension treatment approaches,” said Mark Mallon, CEO of George Medicines.

If you have high blood pressure and are struggling to keep it under control, talk to your doctor about whether a combination therapy might be right for you.